Recent share performance and business context

Stoke Therapeutics (STOK) has given investors a mixed ride recently, with the stock down about 10% over the past month and 15% over the past 3 months, despite a much stronger total return over the past year.

At a recent close of US$30.01 and a market value of about US$1.88b, the company sits squarely in mid cap territory, backed by a focused pipeline built around its TANGO platform for treating severe genetic diseases.

Recent trading has cooled after a strong run, with the share price return down over the past quarter but the 1 year total shareholder return still very strong. This suggests earlier optimism is now being reassessed as investors weigh trial progress, cash needs, and execution risks.

If you are comparing Stoke Therapeutics with other growth stories in healthcare and genetics, this is a good moment to see what else is on your radar through 39 healthcare AI stocks

With Stoke Therapeutics trading at US$30.01, a value score of 3 and a large discount to the average analyst price target, the key question is whether the stock is undervalued or whether markets already reflect expectations for future growth.

Most Popular Narrative: 12.4% Undervalued

On the latest widely followed narrative, Stoke Therapeutics' fair value of $34.25 sits above the recent $30.01 close, putting a spotlight on what assumptions are driving that gap.

The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.

Curious what underpins that higher fair value? Revenue forecasts, margin assumptions and a steep future earnings multiple all sit at the core of this narrative. The full breakdown shows how those moving parts fit together.

Result: Fair Value of $34.25 (UNDERVALUED)

However, this depends on Phase 3 results and regulatory decisions; weaker data or slower approvals could quickly challenge the current undervalued narrative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Sitting between enthusiasm about the upside and caution around the risks, this is a moment to act quickly and test the story against the data. To weigh both sides for yourself, check our breakdown of 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss out on other opportunities that better fit your goals, risk comfort, and income needs.

• Supercharge your watchlist by comparing potential bargains across sectors using the 49 high quality undervalued stocks.
• Prioritise resilience and sleep easier at night by scanning companies highlighted in the 64 resilient stocks with low risk scores.
• Build a portfolio that works for you with dependable cash payouts sourced from the 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.